Sulcardine

Drug Profile

Sulcardine

Alternative Names: HBI-3000; Sulcardine sulphate

Latest Information Update: 18 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Furui Pharmaceuticals; Shanghai Institute of Materia Medica
  • Developer HUYA Bioscience International; Jiangsu Furui Pharmaceuticals
  • Class Antiarrhythmics; Small molecules
  • Mechanism of Action Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Atrial fibrillation
  • Preclinical Arrhythmias

Most Recent Events

  • 10 Jul 2018 HUYA Bioscience International, in collaboration with Quotient Clinical completes a phase I trial in Atrial fibrillation (In volunteers) in United Kingdom (IV) (NCT03397641)
  • 24 Jun 2018 Biomarkers information updated
  • 17 Oct 2017 Phase-I clinical trials in Atrial fibrillation (In volunteers) in United Kingdom (IV) (NCT03397641)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top